Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
Completed
Kowa Research Europe
Phase 3
2006-08-01
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind
extension study for patients who participated in study NK-104-305.
Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)
Terminated
Chieko Hamada
N/A
2009-02-01
The purpose of this study is to verify whether pitavastatin prevents from cardiovascular
events and improves the mortality in chronic hemodialysis patients with hypercholesteremia.
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
Completed
JW Pharmaceutical
Phase 4
2008-04-01
A randomized, open label, dose titration study to evaluate the efficacy and safety of
Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia
Completed
JW Pharmaceutical
Phase 4
2009-06-01
Statin is an effective drug to treat hyperlipidemia (hypercholesterolemia), and it rarely
leads to hepatic damage to the patients with hepatic disorder. For these patients, intensive
monitoring is required.
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Completed
Kowa Research Institute, Inc.
Phase 4
2010-10-01
Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg
daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed
dyslipidemia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
